WHAT IS SIMPONI ARIA® (golimumab)?

SIMPONI ARIA® is the only IV anti-TNFα biologic1-6 approved for the treatment of:

  • Active PsA in patients 2 years of age and older
  • Adult patients with moderately to severely active RA in combination with MTX
  • Adult patients with active Ankylosing Spondylitis
  • Active polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years of age and older

Our Heritage

BlueciWhitecirclercle

YEARS OF EXPERIENCE WITH SIMPONI ARIA®1

BlueciWhitecirclercle

YEARS OF EXPERIENCE WITH Johnson & Johnson Immunology1

SIMPONI ARIA® demonstrated:

  • Improvement in signs and symptoms in adult patients with PsA and RA
    (ACR20 response at Week 14) and AS (ASAS20 response at Week 16)1
Bluecircle
  • The first anti-TNFα biologic with improvement in both the mental and physical components of SF-36, shown in the label, across PsA, RA, and AS in adult patients1,3
  • The first anti-TNFα biologic with improvement in fatigue shown in the label as measured by FACIT-F across PsA and RA in adult patients1-6
  • Demonstrated safety profile1
  • Efficient infusion1
    • A 30-minute infusion given once every 8 weeks—as few as 6 times a year—after starter doses*
    • Liquid solution in a single-use vial with no reconstitution required
    • Weight-based dosing for adult patients

*“Efficient” is defined as the total amount of time required to administer SIMPONI ARIA®. For adult patients with RA, PsA, or AS, 2 mg/kg is administered as an intravenous infusion over 30 minutes once every 8 weeks, after starter doses at Weeks 0 and 4. For adult patients with moderately to severely active RA, SIMPONI ARIA® is given in combination with MTX. For pediatric patients with pJIA or PsA, 80 mg/m2 of SIMPONI ARIA® is administered as an intravenous infusion over 30 minutes at Weeks 0 and 4, and every 8 weeks thereafter.1

Learn more about SIMPONI ARIA® for:

RA

Adult Patients with Moderately to Severely Active Rheumatoid Arthritis IN COMBINATION WITH METHOTREXATE1

PsA

active psoriatic arthritis
in patients 2 years and older1

AS

Adult Patients with active ankylosing spondylitis1

ACR20=20% improvement in American College of Rheumatology criteria; AS=ankylosing spondylitis; ASAS20=20% improvement in Assessment of SpondyloArthritis international Society criteria; FACIT-F=Functional Assessment of Chronic Illness Therapy–fatigue; IV=intravenous; MTX=methotrexate; pJIA=polyarticular juvenile idiopathic arthritis; PsA=psoriatic arthritis; RA=rheumatoid arthritis; SF-36=36-item short-form survey; TNFα=tumor necrosis factor alpha; TNF=tumor necrosis factor.

References: 1. SIMPONI ARIA® (golimumab) [Prescribing Information]. Horsham, PA: Johnson & Johnson. 2. SIMPONI® (golimumab) [Prescribing Information]. Horsham, PA: Johnson & Johnson. 3. REMICADE® (infliximab) [Prescribing Information]. Horsham, PA: Johnson & Johnson. 4. Enbrel® (etanercept) [Prescribing Information]. Thousand Oaks, CA: Immunex Corporation. 5. Humira® (adalimumab) [Prescribing Information]. North Chicago, IL: AbbVie Inc. 6. Cimzia® (certolizumab pegol) [Prescribing Information]. Smyrna, GA: UCB, Inc.